Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Bruna Pellini; Jeffrey Szymanski; Re I. Chin; Paul A. Jones; Aadel A. Chaudhuri

doi:10.1016/j.thorsurg.2020.01.005

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Bruna Pellini, Jeffrey Szymanski, Re I. Chin, Paul A. Jones, Aadel A. Chaudhuri

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such as the challenge of detecting low-level ctDNA variants and distinguishing tumor-related variants from clonal hematopoiesis remain. With further technical advancements, new applications for ctDNA analysis are emerging including detection of post-treatment molecular residual disease (MRD), clinical trial selection, and early cancer detection. This chapter reviews the current state of ctDNA testing in NSCLC, the underlying technological advances enabling ctDNA detection, and the potential to expand ctDNA analysis to new applications.

Original language	English
Pages (from-to)	165-177
Number of pages	13
Journal	Thoracic surgery clinics
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/j.thorsurg.2020.01.005
State	Published - May 1 2020

Keywords

Circulating tumor DNA (ctDNA)
Liquid biopsy
Non-small cell lung cancer (NSCLC)
Plasma genotyping

Access to Document

10.1016/j.thorsurg.2020.01.005

Cite this

@article{58d9e63940a542799f98387dee349d1a,

title = "Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer",

abstract = "Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such as the challenge of detecting low-level ctDNA variants and distinguishing tumor-related variants from clonal hematopoiesis remain. With further technical advancements, new applications for ctDNA analysis are emerging including detection of post-treatment molecular residual disease (MRD), clinical trial selection, and early cancer detection. This chapter reviews the current state of ctDNA testing in NSCLC, the underlying technological advances enabling ctDNA detection, and the potential to expand ctDNA analysis to new applications.",

keywords = "Circulating tumor DNA (ctDNA), Liquid biopsy, Non-small cell lung cancer (NSCLC), Plasma genotyping",

author = "Bruna Pellini and Jeffrey Szymanski and Chin, {Re I.} and Jones, {Paul A.} and Chaudhuri, {Aadel A.}",

year = "2020",

month = may,

day = "1",

doi = "10.1016/j.thorsurg.2020.01.005",

language = "English",

volume = "30",

pages = "165--177",

journal = "Thoracic surgery clinics",

issn = "1547-4127",

number = "2",

}

TY - JOUR

T1 - Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

AU - Pellini, Bruna

AU - Szymanski, Jeffrey

AU - Chin, Re I.

AU - Jones, Paul A.

AU - Chaudhuri, Aadel A.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such as the challenge of detecting low-level ctDNA variants and distinguishing tumor-related variants from clonal hematopoiesis remain. With further technical advancements, new applications for ctDNA analysis are emerging including detection of post-treatment molecular residual disease (MRD), clinical trial selection, and early cancer detection. This chapter reviews the current state of ctDNA testing in NSCLC, the underlying technological advances enabling ctDNA detection, and the potential to expand ctDNA analysis to new applications.

AB - Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such as the challenge of detecting low-level ctDNA variants and distinguishing tumor-related variants from clonal hematopoiesis remain. With further technical advancements, new applications for ctDNA analysis are emerging including detection of post-treatment molecular residual disease (MRD), clinical trial selection, and early cancer detection. This chapter reviews the current state of ctDNA testing in NSCLC, the underlying technological advances enabling ctDNA detection, and the potential to expand ctDNA analysis to new applications.

KW - Circulating tumor DNA (ctDNA)

KW - Liquid biopsy

KW - Non-small cell lung cancer (NSCLC)

KW - Plasma genotyping

UR - http://www.scopus.com/inward/record.url?scp=85084030232&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2020.01.005

DO - 10.1016/j.thorsurg.2020.01.005

M3 - Review article

C2 - 32327175

AN - SCOPUS:85084030232

SN - 1547-4127

VL - 30

SP - 165

EP - 177

JO - Thoracic surgery clinics

JF - Thoracic surgery clinics

IS - 2

ER -

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this